Chris: You are correct about small biotechs needing to dilute. The question is for how long? There needs to be a happy medium, a balance between dilution and deals that actually raise the stock price. Not everyone is willing to lay down $100,000 in a risky investment where the CEO indicates substantial shareholder increases in value are just around the corner....but they don't come for several years.

There needs to be a balance. None of us thought in the Fall of 2013 that we'd be trading at .084 cents the last week of 2014. We all would have sold out and put our money in biotechs that we thought were closer to a pay day.

But 2014 is behind us and good things appear to be right in front of us. Monday will bring LymPro LP002 data. January will bring news of LymPro sales (I hope), and maybe it will bring news on how AMBS plans on "monetizing" our LymPro asset in preparation for up listing and spin off. If things work out the way Gerald has been telling us they will, we still may need a RS, but our shareholder value will have been substantially increased!!